CASI Pharmaceuticals (CASIF) Operating Leases (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Operating Leases came in at $1.4 million in Q4 2025, down 43.16% YoY from $2.5 million in Q4 2024, and down 43.16% on a QoQ basis from $2.5 million in Q4 2024.
CASI Pharmaceuticals (CASIF) Operating Leases (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Operating Leases data on file, last reported at $1.4 million in Q4 2025.
- Quarterly Operating Leases fell 43.16% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 43.16% YoY) and the FY2025 annual result came in at $1.4 million, down 43.16% from the prior year.
- Operating Leases retreated to $1.4 million in Q4 2025, from $2.5 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $2.5 million in Q4 2024 to a low of $476000.0 in Q4 2022.
- A 5-year average of $1.4 million and a median of $1.4 million in 2025 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases plunged 56.92% — and 2023, when it jumped 239.5%.
- Tracing CASIF's Operating Leases over 5 years: stood at $1.1 million in 2021, then sank by 56.92% to $476000.0 in 2022, then jumped by 239.5% to $1.6 million in 2023, then soared by 56.87% to $2.5 million in 2024, then tumbled by 43.16% to $1.4 million in 2025.
- The last three Operating Leases figures came in at $1.4 million (Q4 2025), $2.5 million (Q4 2024), and $1.6 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Dec 31, 2023 | 1.62 Mn |
| Dec 31, 2022 | 476,000.00 |
| Dec 31, 2021 | 1.11 Mn |